Get the Stockscreener App
0.86
0.06%
0.0005
After Hours:
.89
0.03
+3.49%
Context Therapeutics Inc stock is traded at $0.86, with a volume of 58,135.
It is up +0.06% in the last 24 hours and up +2.26% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.8595
Open:
$0.905
24h Volume:
58,135
Relative Volume:
0.23
Market Cap:
$77.15M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.9451
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
-4.95%
1M Performance:
+2.26%
6M Performance:
+6.16%
1Y Performance:
-65.60%
1-Day Range:
$0.8596
$0.905
1-Week Range:
$0.8451
$0.91
52-Week Range:
$0.49
$2.5899
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.86 | 77.10M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Top chart patterns to watch in Context Therapeutics Inc.Weekly Risk Summary & Precise Trade Entry Recommendations - Newser
Is Context Therapeutics Inc. forming a reversal patternGap Up & Community Consensus Trade Alerts - Newser
Is Context Therapeutics Inc. reversing from oversold territoryJuly 2025 Fed Impact & Real-Time Market Trend Scan - Newser
Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Full technical analysis of Context Therapeutics Inc. stock2025 AllTime Highs & Consistent Return Strategy Ideas - Newser
Best data tools to analyze Context Therapeutics Inc. stockPortfolio Return Summary & Safe Entry Momentum Tips - Newser
Context Therapeutics shares rise 1.74% intraday after announcing participation in upcoming investor conferences. - AInvest
Will Context Therapeutics Inc. stock recover after recent drop2025 Bull vs Bear & AI Forecasted Stock Moves - Newser
Will Context Therapeutics Inc. rebound enough to break evenTrade Entry Report & Reliable Price Breakout Signals - Newser
How to use a screener to detect Context Therapeutics Inc. breakoutsJuly 2025 Setups & Expert Verified Stock Movement Alerts - Newser
Is Context Therapeutics Inc. forming a bottoming baseJuly 2025 Volume & Growth Focused Stock Reports - Newser
Clinical-Stage Biotech Context Therapeutics Announces Double-Header Healthcare Conference Schedule - Stock Titan
Is this a good reentry point in Context Therapeutics Inc.July 2025 Retail & Smart Allocation Stock Tips - Newser
How Context Therapeutics Inc. stock performs during market volatilityJuly 2025 Technicals & Real-Time Stock Movement Alerts - Newser
Volume Surge May Signal Institutional Interest in Context Therapeutics Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
Chart based exit strategy for Context Therapeutics Inc.Exit Point & Weekly Watchlist for Hot Stocks - Newser
Does Context Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Fed Impact & Accurate Buy Signal Notifications - Newser
Short interest data insights for Context Therapeutics Inc.Weekly Stock Report & Technical Analysis for Trade Confirmation - Newser
Quantitative breakdown of Context Therapeutics Inc. recent moveJuly 2025 Sentiment & Verified Momentum Watchlists - Newser
What high frequency data says about Context Therapeutics Inc.Weekly Investment Summary & Stock Timing and Entry Methods - Newser
Earnings visualization tools for Context Therapeutics Inc.Inflation Watch & High Return Trade Guides - Newser
How Resilient Is Context Therapeutics Inc. Stock During Economic DownturnsQuarterly Investment Review & Reliable Volume Spike Alerts - Newser
HER2 Negative Metastatic Breast Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc., - Barchart.com
Is it time to cut losses on Context Therapeutics Inc.2025 Support & Resistance & Safe Entry Trade Signal Reports - Newser
What analysts say about Context Therapeutics Inc. stock outlook2025 Valuation Update & Stepwise Entry and Exit Trade Signals - Newser
Context Therapeutics Inc. Shows Early Signs of Technical StrengthFed Meeting & Stock Market Timing Techniques - newsyoung.net
Visual analytics tools that track Context Therapeutics Inc. performanceJuly 2025 Analyst Calls & Weekly High Momentum Picks - Newser
Context Therapeutics Inc. Stock Support and Resistance Levels You Should Know2025 Fundamental Recap & Daily Volume Surge Trade Alerts - Newser
Published on: 2025-08-27 07:10:57 - Newser
What to do if you’re stuck in Context Therapeutics Inc.Portfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Context Therapeutics Reports Q2 2025 Financial Results: Increased R&D Expenses and Strong Cash Position - AInvest
Context Therapeutics Reports Q2 2025 Financial Results - TipRanks
Aug Opening: Is Context Therapeutics Inc. a play on infrastructure spendingJuly 2025 EndofMonth & Expert Curated Trade Setup Alerts - sundaytimes.kr
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MSN
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):